Genzyme: New Framingham plant begins shipping Fabrazyme drug
Genzyme Corp. said today that it has begun shipping doses of its Fabrazyme drug from its new plant in Framingham. The move follows an announcement in January that federal regulators had given Cambridge-based Genzyme the approval to begin producing Fabrazyme at the company’s new Framingham plant. With the Framingham plan coming on line, patients in the United States are now able to return to full dosing following a shortage. Fabrazyme treats Fabry’s disease, a rare enzyme deficiency.